-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
-
Summary
-
BridgeBio Pharma, Inc. quarterly/annual Amortization of Intangible Assets history and growth rate from 2021 to 2023.
- BridgeBio Pharma, Inc. Amortization of Intangible Assets for the quarter ending September 30, 2024 was $600K, unchanged year-over-year.
- BridgeBio Pharma, Inc. Amortization of Intangible Assets for the twelve months ending September 30, 2024 was $2.4M, a 14.3% increase year-over-year.
- BridgeBio Pharma, Inc. annual Amortization of Intangible Assets for 2023 was $2.4M, unchanged from 2022.
- BridgeBio Pharma, Inc. annual Amortization of Intangible Assets for 2022 was $2.4M, a 7.69% decline from 2021.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Annual (USD)
Amortization of Intangible Assets, YoY Annual Growth (%)